13,276 Shares in Incyte Co. (NASDAQ:INCY) Bought by Tobam

Tobam acquired a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 13,276 shares of the biopharmaceutical company's stock, valued at approximately $878,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Incyte by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 22,715,821 shares of the biopharmaceutical company's stock valued at $1,294,120,000 after purchasing an additional 196,440 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Incyte by 28.0% in the second quarter. Acadian Asset Management LLC now owns 3,560,989 shares of the biopharmaceutical company's stock valued at $215,833,000 after purchasing an additional 779,243 shares during the period. LSV Asset Management boosted its stake in shares of Incyte by 0.5% during the 2nd quarter. LSV Asset Management now owns 2,769,892 shares of the biopharmaceutical company's stock valued at $167,911,000 after buying an additional 15,115 shares during the last quarter. Pacer Advisors Inc. grew its stake in Incyte by 17,460.4% in the second quarter. Pacer Advisors Inc. now owns 2,692,182 shares of the biopharmaceutical company's stock worth $163,200,000 after purchasing an additional 2,676,851 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Incyte by 70.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company's stock worth $159,905,000 after buying an additional 1,101,041 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company's stock.

Incyte Trading Down 0.6 %

Shares of NASDAQ:INCY traded down $0.39 on Thursday, reaching $65.37. 1,101,061 shares of the company traded hands, compared to its average volume of 2,398,210. Incyte Co. has a 52 week low of $50.27 and a 52 week high of $70.36. The company has a current ratio of 1.92, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $64.25 and its 200 day simple moving average is $60.45. The stock has a market capitalization of $14.68 billion, a P/E ratio of 19.62, a price-to-earnings-growth ratio of 5.17 and a beta of 0.73.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the company posted $0.77 EPS. The business's revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, equities analysts anticipate that Incyte Co. will post 0.66 EPS for the current fiscal year.

Insider Buying and Selling at Incyte

In related news, insider Thomas Tray sold 572 shares of Incyte stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the sale, the insider now owns 24,825 shares in the company, valued at $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Thomas Tray sold 572 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the sale, the insider now directly owns 24,825 shares of the company's stock, valued at $1,562,485.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vijay K. Iyengar sold 15,571 shares of Incyte stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the transaction, the executive vice president now directly owns 36,701 shares of the company's stock, valued at approximately $2,569,070. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,899 shares of company stock valued at $1,736,746 in the last 90 days. Insiders own 17.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on INCY. Guggenheim lifted their target price on Incyte from $86.00 to $92.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Wells Fargo & Company dropped their price target on Incyte from $63.00 to $62.00 and set an "equal weight" rating on the stock in a report on Thursday. William Blair reaffirmed an "outperform" rating on shares of Incyte in a report on Monday, September 9th. Royal Bank of Canada reissued a "sector perform" rating and set a $67.00 target price on shares of Incyte in a research note on Tuesday, September 3rd. Finally, BMO Capital Markets reaffirmed an "underperform" rating and issued a $48.00 target price (down previously from $52.00) on shares of Incyte in a research report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $73.21.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.